SCHEMBL468815

SCHEMBL468815

CC(=O)NC(CO)C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45
ALOX15 P16050 1/20 0.45
NFKB1 P19838 1/20 0.45
PTGS2 P35354 1/20 0.45
THPO P40225 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TGFBR1 P36897 3/20 0.43
ALDH1A1 P00352 1/20 0.43
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM1 P11229 1/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
SIRT5 Q9NXA8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL468816 1.00 KDM4E (0.45) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1576871 1.00 KDM4E (0.45) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL15826905 0.85 MAPT (0.48) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1909473 0.85 MAPT (0.48) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL16494295 0.84 GNPAT (0.56) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL13930086 0.84 ECE1 (0.44) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL27857327 0.84 GNPAT (0.56) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL8134268 0.81 KDM4E (0.45) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL13953561 0.81 KDM4E (0.45) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL27410307 0.81 KDM4E (0.45) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4137496-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Beijing Greatway Pharmaceutical Technology Co., Ltd. (CN) 2023-02-22 EP disclosed
EP-2311452-B2 Topical composition comprising n-acetyl glucosamine YU RUEY J (US) 2020-12-30 EP disclosed
US-20190134052-A1 DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR NOVARTIS AG (CH) 2019-05-09 US disclosed
EP-2753642-B1 GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2017-03-01 EP disclosed
US-9579320-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2017-02-28 US disclosed
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2015-10-22 US disclosed
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2015-10-22 US disclosed
EP-2295402-B1 Antibacterial agents UNIV WASHINGTON (US) 2015-08-12 EP disclosed
EP-2323993-B1 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS PORTOLA PHARM INC (US) 2015-06-03 EP disclosed
US-20150141426-A1 DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR NOVARTIS PHARMACEUTICALS CORPORATION 2015-05-21 US disclosed
US-6524593-B1 Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails TRISTRATA, INC. 2003-02-25 US disclosed
EP-1143925-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2001-10-17 EP disclosed
EP-0888289-B1 ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES RES CORP TECHNOLOGIES INC (US) 2001-06-13 EP disclosed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 US disclosed
EP-1038522-A2 Anticonvulsant enantiomeric amino acid derivatives Research Corporation Technologies, Inc (US) 2000-09-27 EP disclosed
WO-2000040217-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-07-13 WO disclosed
EP-0888289-A1 ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES Research Corporation Technologies, Inc (US) 1999-01-07 EP disclosed
US-5773475-A DIPEPTIDES FOR CENTRAL NERVOUS SYSTEM DISORDERS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1998-06-30 US disclosed
WO-1997033861-A1 ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1997-09-18 WO disclosed
EP-0416097-A1 PROCESS FOR PRODUCING TROPANE ALKALOIDS SEITAIKINOU RIYOU KAGAKUHIN SHINSEIZOUGIJUTSU KENKYU KUMIAI (JP) 1991-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 KDM4E 1120/4885MAPT 985/4885THRB 1115/4885
US-20150141426-A1 DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR PIK3CA, PIK3CD, PIK3R5 KDM4E 2343/4885MAPT 3409/4885THRB 3682/4885
US-20190134052-A1 DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR PIK3CA, PIK3CD, PIK3R5 KDM4E 2343/4885MAPT 3409/4885THRB 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.